Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

The goal of this clinical trial is to test dapagliflizone in Fabry patients. The main questions it aims to answer are: * Has 10 mg/d of dapagliflozin a positive effect on kidney functions of Fabry patients. * Has 10 mg/d of dapagliflozin a positive effect on heart functions in Fabry patients. Participants will be asked to * Sign an informed consent * Give a blood and urine samples * Be subjected to Echocardiography investigation * Take 10 mg/day Dapagliflizone Researchers will compare treatment to placebo groups to see if kidneys and heart functions will be improved in the treatment group better more than the placebo group.